Display options
Cite
Mackenzie JE, Marshall RJ, Parratt JR. The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function. Br J Pharmacol. 1986;89(2):313-9doi: 10.1111/j.1476-5381.1986.tb10262.x.
Mackenzie, J. E., Marshall, R. J., & Parratt, J. R. (1986). The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function. British journal of pharmacology, 89(2), 313-9. https://doi.org/10.1111/j.1476-5381.1986.tb10262.x
Mackenzie, J E, et al. "The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function." British journal of pharmacology vol. 89,2 (1986): 313-9. doi: https://doi.org/10.1111/j.1476-5381.1986.tb10262.x
Mackenzie JE, Marshall RJ, Parratt JR. The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function. Br J Pharmacol. 1986 Oct;89(2):313-9. doi: 10.1111/j.1476-5381.1986.tb10262.x. PMID: 3779213; PMCID: PMC1917022.
Copy Download .nbib Format: NLM
Share it on
Full text links
Wiley Free PMC Article

Br J Pharmacol. 1986 Oct;89(2):313-9. doi: 10.1111/j.1476-5381.1986.tb10262.x.

The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function.

British journal of pharmacology

J E Mackenzie, R J Marshall, J R Parratt

PMID: 3779213 PMCID: PMC1917022 DOI: 10.1111/j.1476-5381.1986.tb10262.x
Free PMC Article

Abstract

The haemodynamic, metabolic and regional blood flow effects of the vasodilator, tolmesoxide (1 mg kg-1 min-1 for 20 min by intravenous infusion) were examined in two groups of greyhound dogs anaesthetized with alpha-chloralose and mechanically ventilated. One group of dogs was thoracotomized and subjected to acute coronary artery occlusion. In these dogs tolmesoxide was infused 2.5 h after occlusion when there was evidence of impaired myocardial function. Tolmesoxide administration resulted in marked systemic hypotension which was associated with myocardial stimulation (increase in heart rate and LVdP/dtmax). These effects were less marked in thoracotomized dogs subjected to coronary artery occlusion. Cardiac stimulation was attenuated by pretreatment with the beta-adrenoceptor antagonist, atenolol. Peripheral resistance and left ventricular end-diastolic pressure (LVEDP) were reduced by tolmesoxide. In spite of the systemic hypotension, the marked reduction in LVEDP resulted in an enhanced subendocardial driving pressure and an increased blood flow to ischaemic regions of the left ventricular wall as measured with Xe133 clearance. Blood flow to normal regions of the left ventricular wall was also increased by tolmesoxide. A metabolic and respiratory acidosis may have contributed to the haemodynamic effects of tolmesoxide. Plasma renin levels were significantly elevated by the drug. Tolmesoxide administration thus resulted in cardiac stimulation, reduced both pre-load and after-load, yet maintained coronary and pulmonary perfusion. This haemodynamic profile of tolmesoxide would explain the beneficial effects obtained with this drug in the treatment of cardiac failure.

Similar articles

References

  1. Circulation. 1968 Apr;37(4):524-33 - PubMed
  2. Eur J Clin Pharmacol. 1982;23(2):93-7 - PubMed
  3. Cardiovasc Res. 1974 Mar;8(2):204-15 - PubMed
  4. Clin Exp Pharmacol Physiol. 1974 Mar-Apr;1(2):99-112 - PubMed
  5. Br J Clin Pharmacol. 1978 Jan;5(1):35-44 - PubMed
  6. Br J Pharmacol. 1978 May;63(1):111-8 - PubMed
  7. Cardiovasc Res. 1978 Feb;12(2):120-6 - PubMed
  8. Br J Pharmacol. 1980;71(2):597-600 - PubMed
  9. Eur J Clin Pharmacol. 1981 Jan;19(2):113-8 - PubMed
  10. Eur J Clin Pharmacol. 1981 Jan;19(2):119-25 - PubMed
  11. J Physiol (Paris). 1980;76(7):791-803 - PubMed
  12. Am Heart J. 1981 Sep;102(3 Pt 2):500-8 - PubMed
  13. Br J Pharmacol. 1981 Aug;73(4):799-805 - PubMed
  14. Arch Int Pharmacodyn Ther. 1981 Jun;251(2):322-34 - PubMed
  15. Eur J Clin Pharmacol. 1981;21(3):169-72 - PubMed
  16. Eur J Clin Pharmacol. 1982;21(6):473-7 - PubMed
  17. Med Clin North Am. 1970 May;54(3):617-29 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources